Innovative Strategies for the Treatment of Filariasis in Central Africa

Jérémy Campillo, a researcher at the Institute for Research and Development, has identified alternative strategies for the treatment of filariasis in Central Africa. His research demonstrates that semi-annual administration of albendazole and the use of levamisole could reduce the risks associated with ivermectin in co-endemic areas, thereby improving the safety of treatments for vulnerable populations.

The elimination of filariasis, such as onchocerciasis and lymphatic filariasis, remains a challenge in Central Africa. Current treatments, based on ivermectin and albendazole, present risks, particularly in co-endemic areas where Loa loa is present. This research addresses the issue of treatment safety while seeking to ensure effective control of these parasitic diseases.

The results of this study show that semi-annual administration of albendazole can be a viable solution in co-endemic areas. Furthermore, the use of levamisole could reduce microfilaria levels of Loa loa, thus allowing for safer use of ivermectin. These approaches could transform the fight against filariasis by providing alternatives to existing treatments.

The implications of these results are significant for decision-makers and public health stakeholders. The development of alternative treatments could improve the health of populations in Central Africa. Governments and investors should consider these new strategies to strengthen filariasis control programs and meet the growing demand for effective solutions.

« « The semi-annual administration of albendazole could provide a viable solution to reduce the risks associated with ivermectin in co-endemic areas, » says Jérémy Campillo. »

« « This research opens new perspectives for public health decision-makers by highlighting effective alternatives to combat filariasis in Central Africa, » emphasizes the Lektaris team. »